KR101297726B1 - Composition for treating diabete-induced complication containing an extract from Ligularia fischeri - Google Patents

Abstract

Provided is a composition for preventing and / or improving diabetic complications comprising Ligularia fischeri extract or a fraction of the extract as an active ingredient.

Description

Composition for treating diabete-induced complication containing an extract from Ligularia fischeri}

The present invention bear ( Ligularia fischeri ) extract or a composition for the prevention and / or improvement of diabetic complications containing the extract as an active ingredient.

Diabetes mellitus is a chronic disease that has been attracting attention worldwide because of the recent increase in the level of living standards of modern people and the increase in the longevity of human life.

Diabetes mellitus is a metabolic syndrome characterized by a deficiency of insulin hormone or insulin resistance in the beta cells of the pancreas, as well as hyperglycemia resulting from both of these defects. Such diabetes can be divided into insulin-dependent diabetes mellitus (IDDM) and insulin-dependent diabetes mellitus (NIDDM) (Type II) caused by insulin resistance and insulin secretory damage.

Diabetes mellitus, chronic hyperglycemia, as well as lipid metabolism, lipid and protein metabolic disorders are also caused. The condition is diverse and is directly caused by hyperglycemia, and includes diabetic peripheral neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cataract, keratosis, and diabetic atherosclerosis in the retina, the kidney, the nervous system, and the cardiovascular system. The number of diabetic patients is steadily increasing due to changes in lifestyle such as overeating, lack of exercise, westernized eating habits, stress, drinking and smoking.

In Type I and Type II diabetes, diverse complications such as heart disease, bowel disease, ophthalmic disease, neurological disease, and stroke occur, which can lead to chronic neuropathy and cardiovascular disease due to elevated blood glucose and insulin levels over a long period of time And short-term hypoglycemia and hyperglycemia reaction cause acute complications.

Diabetes mellitus is medication, exercise and diet, and insulin medicines and various blood glucose drugs are used depending on the patient's symptoms. However, diabetes is a complex disease characterized by overgrowth of glucose in the liver, insulin resistance, and decreased glucose tolerance in muscle and adipocytes. Therefore, specific treatment alone can not prevent the occurrence of various side effects. Among them, pharmacotherapy uses insulin and chemicals, which is a constant problem for side effects and patient resistance due to taking medications. Recently, it is possible to treat diabetes by using natural products with low side effects. There is a need for research to treat and further prevent and treat diabetic complications.

Thus, the present inventors have found that bear odor has an excellent effect on the treatment of diabetic complications in addition to the antioxidant effect has been completed the present invention.

Accordingly, one embodiment of the present invention provides a composition for preventing and / or improving diabetic complications containing at least one selected from the group consisting of extracts and fractions of bear odor as an active ingredient.

Another example provides a composition for preventing and / or improving diabetic complications comprising at least one selected from the group consisting of extracts and fractions of bear odor.

Another example provides an antioxidant composition containing at least one selected from the group consisting of extracts and fractions of bear odor as an active ingredient.

Hereinafter, the present invention will be described in more detail.

Provided is a composition for preventing and / or improving diabetic complications comprising an extract of bear and / or a fraction of the extract as an active ingredient.

Ligularia , a representative wild vegetable that grows a lot in Gangwon-do fischeri ) is a type of odor characterized by broad leaves. It is mainly consumed in the form of herbs, raw vegetables and Ssam in Korea (Cho SD and Kim GH 2005), pharmacological components such as chamomile, jacobine, ameleme, polyphenol compounds and flavonoids. As is confirmed (Cho SD and Kim GH 2005, Chang SK et al. 2008), a lot of researches on the biological activity of bear odor at the animal experiment and molecular biological level. Representatively, the cytotoxic effect of bear odor (Ham SS 1998b), the antimutagenic and genotoxic effect (Ham SS 1998a, Jeong SW et al. 1998), and the high polyphenols of bear odor Inhibition of antioxidant effects (Jeong SW et al. 1998, Park JA and Kim MK 1999, Kwon YJ et al. 2002, Kim EY et al. 2004, Chang SK et al. 2008) and blood pressure elevation-enhancing enzyme ACE (angiotensin converting enzyme) The effectiveness (Choi GP et al. 2002) is already well proven scientifically. In terms of nutrition, bear odor is particularly rich in vitamins A, B ₁ , B ₂ , B ₃ , C and β-carotene. Among them, vitamin A (780 RE / 100 g) and β-carotene (4681 μg / 100 g), calcium (241 mg / 100 g), fiber (1.7 g / 100 g) and iron (5.7 mg / 100 g) are known to be relatively high compared to other vegetables. It is estimated to be high.

In the present invention bear ( Ligularia) fischeri ) was used as a short-term screening method for the prevention of diabetic complications. Inhibition of the formation of advanced glycation endproducts and aldose reductase inhibitory activity was confirmed.

       The bear odor used in the present invention is not particularly limited in its form, and the composition of the present invention is characterized by including extracts and / or fractions obtained from the bear odor as an active ingredient.

The bear odor extract may be obtained by a common bear odor extraction method using at least one solvent selected from the group consisting of water and C ₁ to C ₄ straight or branched alcohol or mixture.

       In one embodiment of the present invention, in order to achieve a better anti-diabetic complication effect, the extract may be an ethanol extract obtained by extracting the bear odor with 60 to 80% (v / v) ethanol,

The fraction may be obtained by fractionating the extract into at least one selected from the group consisting of hexane, methylene chloride, ethyl acetate and butanol. More preferably, the fraction may be selected from the group consisting of fractions obtained by applying at least one selected from the group consisting of hexane, methylene chloride, ethyl acetate and butanol in the order of polarity, . For example, the hexane fraction obtained by fractionating the ethanol extract with hexane, the methylene chloride fraction obtained by fractionating the hexane fraction, and the remaining aqueous layer fractionated with methylene chloride. The methylene chloride fraction is separated and the remaining aqueous layer is fractionated with ethyl acetate to obtain the ethyl acetate fraction The butanol fraction obtained by separating the ethyl acetate fraction and the remaining aqueous layer with butanol, and the water fraction remaining after separating the butanol fraction.

 Bear extract may be prepared according to the conventional method for producing a plant extract, preferably by pressure extraction method, reflux extraction method, hot needle extraction method, ultrasonic grinding extraction method, etc., preferably by pressure extraction method, It is not limited to this.

In addition, the extract prepared as described above can be concentrated or removed by concentration filtration and / or lyophilization in a subsequent vacuum filtration step. Thus, the bear extract in the present invention is used in the sense including a dried product dried in a conventional manner and a concentrate concentrated in a conventional method.

The present invention provides a diabetic complication treatment effect of bear extract and fraction composition. Diabetic complications are diabetic complications that lead to hyperglycemia and protein reactions that irreversibly progress to produce advanced glycation endproducts (AGEs) that cross-link with other proteins in the blood or tissue. Specifically, the diabetic complication of the bear extract and / or fractions in the present invention may have a diabetic vascular disorder, diabetic neuropathy or diabetic infection, and the like, preferably diabetic retinopathy, diabetic Cataract, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy, and the like, more preferably diabetic retinopathy, diabetic cataract or diabetic nephropathy.

Diabetic complication treatment of the present invention was tested through the ability to inhibit the formation of advanced glycation end products (AGEs) and aldose reductase (Aldose reductase).

The final glycation products are formed by non - enzymatic glycation through sugar - protein binding and schiff base and amadori product. However, in a chronic hyperglycemic state, perhaps a lipid product is reversibly accelerated by a irreversible reaction that produces a final glycation product and is mass-produced and accumulated in tissues and serum. Thus, the production of the final glycated product is one of the major causes of severe diabetic complications.

It is known that the concentration of the final glycated product in the blood of patients with type 2 diabetes is highly correlated with the presence or severity of cardiovascular disease and also correlates with various animal model studies. The end glycation products produced by non-enzymatic glycation of chronic hyperglycemia and biologic proteins are one of the major causes of diabetic complications. Diabetic complications often occur despite the normal recovery of blood sugar. The final glycation product is a protein glycosylation product accumulated in tissues in proportion to the concentration of hyperglycemia, and exhibits a specific absorbance and fluorescence. Especially, amino groups of proteins cause cross-link reaction with each other. Once the final glycation products are produced, they are not degraded even when blood glucose is normally regulated, and accumulate in the tissues, abnormally changing the structure and function of the tissue, and are known to be involved in atherosclerosis, DNA mutation, senescence, Alzheimer's disease and diabetic complications have.

As the toxicity of aminoguanidine, which is known as an inhibitor of the final glycation endogenous product, has been shown to increase, there is a need for the development of a safe natural product with no toxicity to replace it.

As a result of testing the inhibitory activity on the final glycated product of the bear extract and fractions according to the present invention, it was found to have the effect of inhibiting the production of the final glycated product (see Table 1 and Table 2).

In addition, an increase in the polyol pathway, which is one of the trigger mechanisms of diabetic complications, is a mechanism causing cell damage. Aldose Reductase

reductase) is an enzyme involved in the process of converting glucose from sorbitol to fructose in the polyol pathway. In hyperglycemic conditions, changes in glucose metabolism occur in the cell. When excess glucose enters the cell, it is converted to sorbitol by aldose reductase and converted to fructose by sorbitol dehydrogenase . In the normal glucose state, the Km value (70 mM) of aldose reductase to glucose is high and the concentration of sorbitol in the cell is very low. However, if the intracellular glucose concentration is increased by hyperglycemia, not only the intracellular sorbitol concentration is increased but also the sorbitol dehydrogenase slows down the reaction so that sorbitol accumulates in the cell. Eventually, the high osmotic pressure of sorbitol accumulated in the cells expands the cells and damages the cells, resulting in complications such as cataracts, diabetic neurosis and retinopathy.

Therefore, in the present invention, in order to develop a new natural product that can effectively prevent diabetic complications, we tested the ability to inhibit the aldose reductase activity of the extract and fractions of bear odor. As a result, bear extract and fractions were found to have the ability to inhibit aldose reductase activity (see Table 3 and Table 4).

Bear extract and / or fractions according to the present invention have been shown to have good antioxidant activity. DPPH (1,1-diphenyl-2-picrylhydrazyl) scavenging effect was tested to test the antioxidant effect of the composition of the present invention. DPPH is a compound with chemically stable free cardial and is widely used to check the antioxidant capacity when it meets a substance with antioxidant activity. The electron donating action using DPPH is used for the purpose of inhibiting lipid oxidation in foods by donating electrons to free radicals and is being used in the body to suppress aging by free radicals.

As a result of evaluating the antioxidant activity by testing DPPH radical scavenging ability of the bear extract and / or fractions, it was found that the bear extract and / or fractions had excellent antioxidant ability (see Table 5 and Table 6).

The composition of the present invention is a nutrient, vitamins, electrolytes, flavoring agents, coloring agents, neutralizing agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, in addition to the bear extract and / or fractions as an active ingredient , Stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The components can be added independently or in combination. The content of the additional component is preferably added in the range of 0.1 to 20 parts by weight or 100 to 10,000,000 parts by weight per 100 parts by weight of licoridine, but is not limited thereto. .

The content of the bear extract and / or fractions in the composition can be appropriately adjusted according to the symptoms of the disease, the progress of the symptoms, the condition of the patient, for example, 0.0001 to 99.9% by weight, preferably 0.001 based on the total weight of the composition It is preferably from 50% by weight, but is not limited thereto. The content ratio is a value based on the drying amount from which the solvent is removed.

The composition may further contain an appropriate carrier, excipient and diluent conventionally used in the production of a pharmaceutical composition. The composition may be administered orally or parenterally in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, An external preparation, a suppository or a sterilized injection solution, and the like.

When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient and / or lubricant. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.

The preferred dosage of the composition varies depending on the condition and the weight of the patient, the degree of the disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. For a more preferable effect, the dose of the composition of the present invention is preferably 0.1 mg / kg to 20 mg / kg per day based on the active ingredient, but is not limited thereto. The administration may be carried out once a day or divided into several doses. The compositions of the present invention may be administered to a mammal, including a human, in various ways. All modes of administration may be expected, for example, by oral, intravenous, intramuscular, subcutaneous injection, and the like. The pharmaceutical dosage form of the composition of the present invention may be used in the form of a pharmaceutically acceptable salt of the active ingredient, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable combination.

In another example, there is provided a composition for the prevention and / or improvement of diabetic complications comprising the bear odor extract and / or fraction as described above. In the present invention, the term " food " means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be directly eaten through a certain processing step, , Health functional foods, beverages, food additives and beverage additives. Examples of the food include various foods, beverages, gums, tea, vitamin complex, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, natural flavors (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages and other health supplement foods. The health functional food, beverage, food additive or beverage additive can be produced by a usual production method.

The food composition may comprise a pharmaceutically acceptable food-aid additive and may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of a functional food.

In addition, in the food, the amount of the bear extract and / or fraction may be included in 0.00001% to 50% by weight of the total weight of the food, if the food is a beverage 0.001 g based on 100 ml of the total volume of food To 50 g, preferably 0.01 g to 10 g, but is not limited thereto.

Since the composition comprising bear extract and / or fractions according to the present invention is a composition derived from natural products which is excellent in treating diabetic complications but does not have toxicity and side effects, it can be more safely applied to the treatment of diabetic complications.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are merely illustrative of the present invention, and the scope of the present invention is not limited by these examples.

Material preparation

Ligularia fischeri ) was purchased from Gangwon-do, Yanggu-gun pharmacist, DPPH (1,1-diphenyl-2-picrylhydrazyl), DMSO (dimethyl sulfoxide), BSA (Albumin from bovin serum), methylglyoxal, amino Guanidine (Aminoguanidine), NADPH, DL-glyceraldehyde, Quercetin (Quercetin), NaCO ₃ was purchased from Sigma (USA), and all other reagents used in the analysis were express.

sample Preparation Example 1

Bear extract and fractions of the present invention is added to 10 times 70% ethanol of 1000 g of dried bear odor weight and extracted at 65 ℃ in an aqueous solution for 3 hours and then filtered to obtain an extract. The extraction process is repeated three times. The obtained extract was concentrated under reduced pressure at 40 ° C. or lower, and then freeze-dried to obtain a powdery extract.

sample Production Example 2

Bear odor obtained in Sample Preparation Example 1 To 100 g of the extract, 500 L of distilled water was added, suspended, 500 L of hexane was added thereto, and the mixture was separated into a hexane-soluble fraction and a water-soluble fraction. The same procedure was repeated three times to collect only the hexane soluble fraction, followed by drying under reduced pressure to obtain hexane soluble extract powder. The methylene chloride, ethyl acetate, butanol soluble fraction and water soluble fraction were collected and dried under reduced pressure Powder was obtained.

Example  One. Of final glycation end products (AGEs)  Inhibitory effect test

In this example, to examine the therapeutic effect of diabetic complications, the 24-hour short-term screening method using methylglyoxal was used to determine the effect of suppressing the final glycosylated product (AGEs) of the extracts and fractions of the bear odor on the basis of the blank and the control. Measured.

A sample dissolved in DMSO (dimethyl sulfoxide) in BSA (5 mg / mL) and methylglyoxal (2 mg / mL) (extract and fraction of the odor obtained in Example 1) (11 mg / mL) was added thereto, and 50 mM phosphate buffer ( pH 7.4) was used to adjust the total volume to 5 mL. After reacting at 36 ° C. for 24 hours, the absorbance (Excitation: 355 nm, Emission: 460 nm) of the sample before and after the reaction was measured using a spectrofluorometer (Fluoroskan Ascent FL, Thermo Scientific, USA). The inhibition rate of the absorbance was calculated by comparing the absorbance increase value of the sample based on the absorbance increase value of the control group.

Calculation = {1- (S ₁ -S ₀ ) / (C ₁ -C ₀ )} * 100

(S ₀ : sample 0hr absorbance response value, S ₁ : sample 24hr absorbance response value, C ₀ : control 0hr absorbance response value, and C ₁ : control 24hr absorbance response value). In addition, fluorescence inhibition rates were compared using aminoguanidine (Sigma Chemical Co., St. Louis, Mo., USA) as a standard substance known to have an inhibitory effect on the final glycation end product. The concentrations (IC ₅₀ ) of the samples show a 50% reduction in absorbance relative to the control, and each sample was run three times and averaged.

The obtained results are shown in Table 1 and Table 2. As a result of measuring the increase of fluorescence based on the blank and the control group, the 70% ethanol extract was 71.9% at the concentration of 5.5 mg / mL for the bear extract, showing the highest fluorescence inhibition among the extracts.

In addition, the inhibitory rate and IC ₅₀ of each concentration of the bear odor fraction are shown in Table 2 below.

Table 1. Inhibitory Effect of Bear Extract on AGEs Formation

Table 2. Effect of Inhibitory Formation on AGEs Formation

¹⁾ IC ₅₀ values represent concentrations showing 50% inhibition of AGEs formation. The calculated value is the least-square regression equation for a log curve of three concentrations.

²⁾ Positive Control (Typical AGEs Formation Inhibitors).

As can be seen in Table 1, 2, 70% ethanol extract of Goji odor was shown to have high activity, and the ethyl acetate and butanol fractions had a inhibition rate of 50% at concentrations of 0.795 and 0.621 μg / mL, respectively. appear.

Example  5. Aldos  Reductase ( Aldose reductase Inhibitory efficacy test

The effect of bear extract on aldose reductase activity, a catalytic enzyme of the polyol pathway, a glucose metabolism known to play an important role in the development of diabetic complications, was confirmed. An aldose reductase inhibitor is an enzyme inhibitor that inhibits aldose reductase, which converts glucose into sorbitol, and aims to reduce the production of sorbitol. Since many studies have shown that polyol metabolic abnormalities cause diabetic complications, aldose reductase inhibitors may be useful as treatments for diabetic complications.

Thus, in this embodiment, in order to prove the effect of treating diabetic complications, the ability of inhibiting the aldose reductase activity of the extract and fractions of bear odor.

Lenses weighing more than 200 g (Sprague-Dawly (SD) rats; 250-280 g) were extracted and 0.05 μL sodium buffer (pH 6.8) was added to the lens, depending on the wet weight of the lens therein. Was added to homogenize in ice. After centrifugation (centrifuge UNION 55 R Hanil, Korea) for 30 minutes at 4 ℃, 7500rpm, the supernatant was taken and used as the enzyme source of the aldose reductase test.

The ability to inhibit aldose reductase activity was tested by modifying the method used by Haymanh and Kinoshita (Hayman S, Kinoshita JH. 1965. Isolation and properties of lens aldose reductase. J. Biol. Chem. 240 (2) ): 877-882). Into 530 μL of 0.05M potassium phosphate buffer (pH 7.0), put 160 μL of the above prepared enzyme source, 100 μL of 1.6 mM NADPH (Applichem, Germany), and 10 μL of the sample (Gear extract or fraction obtained in Sample Preparation Example 1, 1 mg / mL). Finally, 100 μL of 0.1M DL-glyceraldehyde (DL-Glyceraldehyde, Sigma, USA) was added. The reaction was allowed to proceed for 4.4 minutes inside the cuvette to measure the decrease rate of NADPH absorbance at 340 nm. The reaction was carried out for 4.4 minutes in the cuvette, and the absorbance values of the samples were calculated with absorbance values of 0s and 280s. Formula 1 = (absorbance value at 0 s-absorbance value at 280 s) / time of reaction} was used. Inhibition rate was used as the following formula.

Calculation = {(control-sample)-(control-blank)}

In addition, using a quercetin (Quercetin, Sigma Chemical Co. (St Louis, MO, USA)) as a control substance known to have an aldose reductase inhibitory effect was measured in the same manner as described above to measure the rate of decrease in absorbance sample Preparation Example 1 It was compared with the results in the samples prepared in, 2. The concentration of the sample (IC ₅₀ ), indicating a 50% reduction in absorbance for the control material, was expressed, and each sample was repeated three times and averaged.

Table 3. Inhibitory Effects of Bear Extracts on Aldose Reductase Activity

Table 4. Inhibitory Effect of Aldose Reductase Activity on the Bear Fraction

¹⁾ IC ₅₀ value represents the concentration showing 50% inhibition of aldose reductase activity,% inhibition vs. The calculated value is the least-square regression equation for a log curve of three concentrations.

²⁾ positive control substance (typical aldose reductase activity inhibitor).

As can be seen in Tables 3 and 4, high activity was observed in the 70% ethanol extract of Goji odor, and accordingly, the ethyl acetate and butanol fractions had 50% inhibition rate at concentrations of 0.003 and 0.013 μg / mL, respectively. appear. The fractions of the odor ethyl acetate and butanol fractions showed much lower concentrations than the IC ₅₀ values of quercetin.

Example  3. DPPH Antioxidant Effect Test

DPPH is a compound with chemically stable free cardial and is widely used to check the antioxidant capacity when it meets a substance with antioxidant activity. Thus, in this embodiment, the antioxidant effect was evaluated by evaluating the free radical scavenging effect (hydrogen donating ability to DPPH) of the extract and fractions of the bear odor extract using DPPH.

Bear extract and each fraction were prepared by diluting with DMSO (dimethyl sulfoxide). 2 mL of 5Χ 10 ^-4 M DPPH solution (dissolved in 99% ethanol) was added to 1 mL of the prepared sample at a constant concentration, mixed well, and left at room temperature for 30 minutes. The obtained reaction solution was measured by electron donating ability at 517 nm absorbance. The inhibitory capacity of each fraction was calculated from the radical scavenging rate from the reduced absorbance compared to the positive control.

Calculation = {1- (Control / Sample)} * 100

At this time, ascorbic acid (Showa Chemicals Inc., Japan), which is known to have an antioxidant effect, was used as a positive control group, and the results were described by measuring DPPH quenching ability by treating the same method as described above. And compared with the content required for 50% inhibition of DPPH free radicals (IC ₅₀ ), and the results obtained by the three repeated experiments the sample is shown as the average value.

The results of comparing DPPH scavenging ability of the extracts of Goji odor and fractions are shown in Tables 5 and 6, respectively.

 Table 5. DPPH Radical Scavenging Effects of Bear Extract

Table 6. DPPH radical scavenging effect of goji odor fraction

In Table 5 and Table 6,

¹⁾ IC ₅₀ value represents the concentration showing 50% inhibition of DPPH radical,% inhibition vs. The calculated value is the least-square regression equation for a log curve of three concentrations.

²⁾ Positive Control (Typical DPPH Radical Scavengers).

As confirmed in Table 5 and Table 6, it was confirmed that the 70% ethanol extract in the extract of Goji odor has excellent oxidation inhibitory ability, fraction based on this to compare the DP ₅₀ radical inhibition activity of the Goji odor fraction by comparing the IC ₅₀ value Ethyl acetate fraction and butanol fraction showed 0.039 and 0.663 ug / mL, respectively. That is, it was confirmed that Goji odor ethyl acetate fraction and methylene chloride fractions have excellent oxidation inhibitory ability.

Statistical processing

Statistical analysis of all data was performed using the SAS statistical program (SAS institute, 1987). The results were expressed as means and standard errors per experiment group. Significance test was performed at the p <0.05 level by Duncan's multiple range test.

Claims (7)

It contains ethyl acetate fraction or butanol fraction, which is obtained by sequentially fractionating the extract of Goji odor with hexane, methylene chloride, ethyl acetate and butanol, as an active ingredient,
A composition for the prevention or improvement of diabetic complications, which has the ability to inhibit the formation of advanced glycation endproducts (AGEs) and the aldose reductase activity.
delete delete delete The method of claim 1,
The diabetic complications are diabetic vascular disorders, diabetic neuropathy or diabetic infectious disease, characterized in that the composition for the prevention or improvement of diabetic complications.
The method of claim 5,
The diabetic complications are diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy or diabetic complications, characterized in that the prevention of diabetic complications Or a composition for improvement. delete